Turn Therapeutics Inc.

# Turn Therapeutics Inc. (TTRX)

Incorporated in Delaware in 2015 and headquartered in Westlake Village, California, Turn Therapeutics operates as a pharmaceutical company focused on dermatology and ophthalmology. The company develops drug formulations and delivery technologies targeting diseases of the skin, nails, and eye. Its core competency centers on penetration technology designed to deliver therapeutics through the skin barrier and into nail tissue, with particular emphasis on wound care applications spanning acute and chronic conditions.

The company's pipeline addresses multiple therapeutic areas including acute and chronic wounds, general skin conditions, and dermatoses. Turn Therapeutics markets solutions intended to reduce antibiotic resistance in healthcare settings while expanding treatment options for various cutaneous and ocular disorders. The company rebranded from Global Health Solutions, Inc. to Turn Therapeutics Inc. in September 2025, reflecting a strategic refocus on its therapeutic development platform.

With a market capitalization of approximately $100 million, Turn Therapeutics represents an early-stage biotechnology company. Detailed information regarding employee count, specific revenue generation, or geographic distribution of operations is not currently available. The company trades on Nasdaq.